Drug Trial Radar · NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Last checked: Nov 19, 2026Latest source record: Jul 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,710
Actual
Start
Sep 15, 2004
Primary completion
Mar 12, 2009
Study completion Dec 31, 2012
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NSABP Foundation Inc
- First posted
- Nov 9, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who have undergone surgery for stage II or stage III colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Giving chemotherapy together with bevacizumab may kill more tumor cells. It is not yet known whether treatment with oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab in treating patients who have undergone surgery for colon cancer.
Conditions
- Colon Adenocarcinoma
- Stage IIA Colon Cancer AJCC v7
- Stage IIB Colon Cancer AJCC v7
- Stage IIC Colon Cancer AJCC v7
- Stage IIIA Colon Cancer AJCC v7
- Stage IIIB Colon Cancer AJCC v7
- Stage IIIC Colon Cancer AJCC v7
Interventions
BevacizumabBiological
Given IV
FluorouracilDrug
Given IV
Leucovorin CalciumDrug
Given IV
OxaliplatinDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free SurvivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Surgical Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.